ÂÜÀòÂÒÂ×

Carol Ashe has held a variety of roles in the biotechnology and pharmaceutical industries. Carol began their career in 1989 at GlaxoSmithKline, where they held the roles of Vice President - Legal Operations (Corporate Functions-US), Vice President & Associate General Counsel / Head Business Development Legal Transactions Team, and Assistant Patent Counsel and Business Development Counsel. In 2009, they joined SR One (GlaxoSmithKline Venture Capital Group) as a Partner. In 2010, they started their own business, Carol Ashe Associates LLC, as a Business Development Transactions Consultant - Biotechnology/Pharmaceutical. In 2011, they moved to Endo Pharmaceuticals as Vice President Corporate Development - Pharmaceuticals and Vice President Corporate Development - Specialty Generics & Technology. In 2018, they became an Independent Board Director at Aptose Biosciences, Inc. and in 2020, they became an Independent Board Director at Elicio Therapeutics. Carol is currently the Chief Business Officer at the New York Genome Center.

Carol Ashe obtained a BS in Biology from Penn State University and a JD in Law from Villanova University Charles Widger School of Law.